Corvus Pharmaceuticals Inc (CRVS)
NASDAQ:CRVS
CRVS Stock Chart & Stats
$14.22
-$0.10(-1.74%)
At close: 4:00 PM EST
$14.22
-$0.10(-1.74%)
Day’s Range― - ―
52-Week Range$2.54 - $26.95
Previous CloseN/A
Volume202.27K
Average Volume (3M)1.32M
Market Cap
$1.19B
Enterprise Value$1.19B
Total Cash (Recent Filing)$56.75M
Total Debt (Recent Filing)$937.00K
Price to Earnings (P/E)―
Beta1.11
Next Earnings
May 11, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding83,992,410
10 Day Avg. Volume1,591,373
30 Day Avg. Volume1,317,093
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)9.93
Price to Sales (P/S)0.00
P/FCF Ratio-18.44
Enterprise Value/Market Cap1.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-45.80K
Enterprise Value/Ebitda-28.05
Forecast
1Y Price Target
$32.00Price Target Upside125.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.6
Revenue Forecast (FY)$1.18M
Bulls Say, Bears Say
Bulls Say
Addressable Market ExpansionPlans to expand development into asthma and hidradenitis suppurativa, together with an analyst's increased projected market penetration and higher price target, point to meaningful commercial upside beyond dermatology.
Clinical Data CatalystsMultiple upcoming readouts from a mid-stage atopic dermatitis trial, interim analyses, and an independent partner study in China could materially change the drug's development outlook if they confirm safety and efficacy.
Clinical Efficacy And TolerabilityEarly clinical data showed clear patient improvement versus placebo and safety comparable to placebo, suggesting the drug may work for patients who previously failed biologic or JAK therapies.
Bears Say
Commercial Execution RiskCommercial challenges such as pricing, payer access, and physician adoption could limit sales even if clinical results are favorable.
Intellectual Property And Financial RiskPotential intellectual property disputes or insufficient funding could impede clinical progress and jeopardize long-term development plans.
Partnership And Development DependencyDependence on external partners for regional studies and program support creates execution risk if collaborators alter priorities or timelines.
Corvus Pharmaceuticals News
CRVS FAQ
What was Corvus Pharmaceuticals Inc’s price range in the past 12 months?
Corvus Pharmaceuticals Inc lowest stock price was $2.54 and its highest was $26.95 in the past 12 months.
What is Corvus Pharmaceuticals Inc’s market cap?
Corvus Pharmaceuticals Inc’s market cap is $1.19B.
When is Corvus Pharmaceuticals Inc’s upcoming earnings report date?
Corvus Pharmaceuticals Inc’s upcoming earnings report date is May 11, 2026 which is in 46 days.
How were Corvus Pharmaceuticals Inc’s earnings last quarter?
Corvus Pharmaceuticals Inc released its earnings results on Mar 12, 2026. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.129 by -$0.021.
Is Corvus Pharmaceuticals Inc overvalued?
According to Wall Street analysts Corvus Pharmaceuticals Inc’s price is currently Undervalued.
Does Corvus Pharmaceuticals Inc pay dividends?
Corvus Pharmaceuticals Inc does not currently pay dividends.
What is Corvus Pharmaceuticals Inc’s EPS estimate?
Corvus Pharmaceuticals Inc’s EPS estimate is -0.15.
How many shares outstanding does Corvus Pharmaceuticals Inc have?
Corvus Pharmaceuticals Inc has 83,992,410 shares outstanding.
What happened to Corvus Pharmaceuticals Inc’s price movement after its last earnings report?
Corvus Pharmaceuticals Inc reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.129. Following the earnings report the stock price went down -4.31%.
Which hedge fund is a major shareholder of Corvus Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in CRVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corvus Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.00 (125.04% Upside)
$32.00 (125.04% Upside)
Blogger Sentiment
Bullish
CRVS Sentiment 75%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 756.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 9.0%
Last 30 Days ▲ 9.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
209.41%
12-Months-Change
Fundamentals
Return on Equity
-23.29%
Trailing 12-Months
Asset Growth
3.21%
Trailing 12-Months
Company Description
Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
CRVS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong positives: robust early efficacy signals (notably cohort 4 AD results), durable responses without rebound, a clean safety profile across >150 patients, supportive biomarker data, favorable PTCL survival metrics versus historical controls, clear plans to expand into multiple indications, and a substantial $189M financing that increases pro forma cash to ~$246M providing runway into Q2 2028. Offsetting factors include materially higher R&D spending, continued quarterly net losses, reliance on small early cohorts pending larger confirmatory trials, timeline uncertainty for registrational data (primary Phase II AD mid-2027; PTCL full readout late 2027), and execution/regulatory risks inherent to multiple concurrent development programs. Overall, the positives (clinical signal, durability, safety, biomarker rationale, and strengthened balance sheet) outweigh the near-term financial and execution challenges, but success depends on upcoming larger trials and interim readouts.View all CRVS earnings summariesCRVS Stock 12 Month Forecast
Average Price Target
$32.00
▲(125.04% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---